Stifel has lowered its price target for Candel Therapeutics from $22 to $19, while reiterating a 'Buy' rating. This adjustment follows the company's recent Q3 financial results and clinical program updates, indicating a revised valuation perspective from the analyst firm.
Stifel, an investment bank, has adjusted its price target for Candel Therapeutics (CADL) from $22 to $19. This change comes after the company's third-quarter financial reporting and updates on its clinical programs, suggesting Stifel has re-evaluated its valuation model based on new information. Despite the lower price target, the firm maintained its 'Buy' rating, indicating continued confidence in the company's long-term prospects, albeit with a slightly reduced near-term valuation. For traders, this could lead to short-term price volatility as the market digests the revised target, but the maintained 'Buy' rating might mitigate significant negative sentiment. The key risk is that other analysts may follow suit with price target reductions, while the opportunity lies in potential undervaluation if the market overreacts to the price target cut despite the maintained positive rating.